Equities Analysts Set Expectations for IN8bio, Inc.’s Q1 2024 Earnings (NASDAQ:INAB)

IN8bio, Inc. (NASDAQ:INAB) – Equities research analysts at Zacks Small Cap issued their Q1 2024 earnings per share estimates for IN8bio in a report issued on Monday, April 22nd. Zacks Small Cap analyst J. Vandermosten forecasts that the company will earn ($0.15) per share for the quarter. The consensus estimate for IN8bio’s current full-year earnings is ($0.70) per share. Zacks Small Cap also issued estimates for IN8bio’s Q2 2024 earnings at ($0.15) EPS, Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.58) EPS, FY2025 earnings at ($0.59) EPS and FY2026 earnings at ($0.60) EPS.

IN8bio (NASDAQ:INAB) last posted its earnings results on Thursday, March 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.05).

Several other equities analysts have also issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of IN8bio in a report on Wednesday, April 10th. Laidlaw began coverage on IN8bio in a research note on Monday, March 18th. They issued a “buy” rating and a $7.50 target price for the company.

IN8bio Stock Up 1.9 %

Shares of NASDAQ INAB opened at $1.06 on Wednesday. The firm has a 50 day moving average price of $1.13 and a 200 day moving average price of $1.16. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.57 and a current ratio of 4.57. The stock has a market cap of $33.91 million, a P/E ratio of -1.05 and a beta of -0.01. IN8bio has a 52-week low of $0.65 and a 52-week high of $3.48.

Institutional Investors Weigh In On IN8bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. AIGH Capital Management LLC bought a new stake in IN8bio in the 4th quarter valued at approximately $5,216,000. Rock Creek Group LP increased its stake in IN8bio by 98.3% in the 3rd quarter. Rock Creek Group LP now owns 151,314 shares of the company’s stock valued at $157,000 after buying an additional 75,000 shares during the last quarter. Voss Capital LLC lifted its position in IN8bio by 11.7% during the 3rd quarter. Voss Capital LLC now owns 511,584 shares of the company’s stock worth $532,000 after buying an additional 53,708 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc boosted its stake in shares of IN8bio by 85.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 78,624 shares of the company’s stock worth $109,000 after buying an additional 36,179 shares during the last quarter. 92.05% of the stock is currently owned by institutional investors and hedge funds.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.